ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2437

Analysis of Occurrence of Small for Gestational Age Infants in Women with Systemic Lupus Erythematosus

Bruna Costa Rodrigues1, Marcela Ignacchiti Lacerda1, Guilherme Ramires de Jesus2, Flavia Cunha dos Santos2, Nilson Ramires de Jesus2, Roger Abramino Levy1,3 and Evandro Mendes Klumb1, 1Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 3Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Lupus, nephritis and pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a higher risk of fetal growth restriction and birth of small for gestational age (SGA) concepts. Fetuses with growth restriction have 10-fold higher neonatal mortality, higher risk of hypoxia, meconium aspiration, hypoglycemia, delay in neurodevelopment and cerebral palsy. In adulthood, there is a greater risk of hypertension, type 2 diabetes, hypercholesterolemia and cardiovascular disease. The present study aims to analyze the occurrence of SGA (birth weight below 10th percentile) newborns (NB) in pregnant women with SLE accompanied at a tertiary unit. We studied the association of birth of SGA infants with clinical and laboratory characteristics of maternal SLE prior to conception, during gestation and with maternal comorbidities.

Methods: This is a cohort study with retrospective and prospective data collection, with inclusion of patients with ≥ 4 SLE classification criteria (ACR), single pregnancies and deliveries after 22 weeks. Patients with fetuses with congenital malformations or aneuploidy were excluded. Data were obtained by script-oriented chart review. The comparison between groups was done using Student’s t-test or Mann-Whitney test for numerical data and chi-square test (χ2) or Fisher’s exact test for categorical data, with significance of 5%.

Results: 151 patients where included,and 28 had SGA NB (18.5%). Of the variables prior to conception, previous history of nephritis (RR = 3.01, 1.28-7.08, p=0.01) and presence of anti-RNP antibody (RR = 2.67, 1.11-6.43, p=0.02) were more frequent in patients with SGA NB. Among variables that occurred during gestation, active nephritis (RR = 4.11, 1.68-10, p=0.002), pulse therapy with methylprednisolone (RR = 20.3, 2.18-190, p=0.008) and consumption of C3 complement (RR = 2.70, 1.09-6.67, p=0.03) were associated with SGA group. When considering the SGA NB with altered fetal Doppler subgroup, the associated additional variables were the presence of permanent damage by SDI ≥ 1 (RR = 7.43, 1.50-36.7, p=0.01), previous history of neurolupus (RR = 5.16, 1.21-21.8, p=0.03), presence of lupus anticoagulant (RR = 4.58, 1.07-19.5, p=0.04), antiphospholipid syndrome (RR = 5.21, 1.26-21.5, p=0.04), activity at conception (RR = 6.27, 1.26-31.1, p=0.02) and during gestation (RR = 6.08, 1.22-30.1, p=0.02 per clinical judgment and RR = 9.67, 1.97-47.5, p=0.004 per SLEPDAI score ≥ 6), extra-renal activity (RR = 6.08, 1.22-30.1, p=0.02), presence of anti-DNA (RR = 4.58, 1.07-19.5, p=0.04) and SLE-related hospitalization during pregnancy (RR = 8.6, 1.74-42.3, p=0.006). Birth weight and gestational age at delivery were lower in the SGA group (1831g +/- 687g vs 2794g +/- 741g, p<0.0001; 36.5 vs 38 weeks, p=0.05). Fetal death and admission to neonatal ICU were 4.3 (p=0.03) and 3.2 (p<0.0001) times more frequent among the SGA NB, as were activity in the puerperium (3.9 times, p=0.02) and peripartum hemorrhage (2.3 times, p=0.04) among women with SGA NB.

Conclusion: These findings reinforce the importance of SLE remission prior to conception, since prior maternal morbidity combined with the presence of disease activity during pregnancy and treatment with high doses of steroids increase the risk of SGA birth.


Disclosure: B. Costa Rodrigues, None; M. Ignacchiti Lacerda, None; G. Ramires de Jesus, None; F. C. dos Santos, None; N. Ramires de Jesus, None; R. A. Levy, GlaxoSmithKline, 3; E. M. Klumb, None.

To cite this abstract in AMA style:

Costa Rodrigues B, Ignacchiti Lacerda M, Ramires de Jesus G, dos Santos FC, Ramires de Jesus N, Levy RA, Klumb EM. Analysis of Occurrence of Small for Gestational Age Infants in Women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/analysis-of-occurrence-of-small-for-gestational-age-infants-in-women-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-occurrence-of-small-for-gestational-age-infants-in-women-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology